Table 2 Disease characteristics in the IL-22 cohort.

From: Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease

 

CD

UC

IL-22 lowa

(n = 1077)

IL-22 highb

(n = 527)

Total

(n = 1604)

IL-22 lowa

(n = 625)

IL-22 highb

(n = 211)

Total

(n = 836)

sCDAI/6-point UCDAI category, n (%)

Remission (sCDAI < 150/6-point UCDAI ≤ 1)

686 (63.7)

273 (51.8)

959 (59.8)

426 (68.2)

107 (50.7)

533 (63.8)

Mild (sCDAI 150–219/6-point UCDAI 2–3)

216 (20.1)

114 (21.6)

330 (20.6)

133 (21.3)

60 (28.4)

193 (23.1)

Moderate (sCDAI 220–450/6-point UCDAI 4–5)

165 (15.3)

125 (23.7)

290 (18.1)

55 (8.8)

30 (14.2)

85 (10.2)

Severe (sCDAI > 450/6-point UCDAI 6)

6 (0.6)

13 (2.5)

19 (1.2)

10 (1.6)

13 (6.2)

23 (2.8)

Missing

4 (0.4)

2 (0.4)

6 (0.4)

1 (0.2)

1 (0.5)

2 (0.2)

CD phenotype

Inflammatory, non-penetrating, non-stricturing

329 (30.5)

130 (24.7)

459 (28.6)

–

–

–

Stricturing

176 (16.3)

96 (18.2)

272 (17.0)

–

–

–

Penetrating

138 (12.8)

84 (15.9)

222 (13.8)

–

–

–

Both stricturing and penetrating

174 (16.2)

101 (19.2)

275 (17.1)

–

–

–

Missing

260 (24.1)

116 (22.0)

376 (23.4)

–

–

–

CD location

Colonic

106 (9.8)

50 (9.5)

156 (9.7)

–

–

–

Ileal

148 (13.7)

51 (9.7)

199 (12.4)

–

–

–

Ileocolonic

396 (36.8)

223 (42.3)

619 (38.6)

–

–

–

Upper GI only

N/A

1 (0.2)

1 (0.1)

–

–

–

Missing

420 (39.0)

199 (37.8)

619 (38.6)

–

–

–

UC phenotype

Ulcerative proctitis

–

–

–

61 (9.8)

21 (10.0)

82 (9.8)

Left-sided

–

–

–

121 (19.4)

32 (15.2)

153 (18.3)

Extensive

–

–

–

45 (7.2)

20 (9.5)

65 (7.8)

Pancolitis

–

–

–

253 (40.5)

73 (34.6)

326 (39.0)

Missing

–

–

–

145 (23.2)

65 (30.8)

210 (25.1)

Extraintestinal manifestations, n (%)

IBD-associated arthropathy

148 (13.7)

90 (17.1)

238 (14.8)

75 (12.0)

23 (10.9)

98 (11.7)

Aphthous ulcer

50 (4.6)

33 (6.3)

83 (5.2)

23 (3.7)

13 (6.2)

36 (4.3)

Erythema nodosum

25 (2.3)

14 (2.7)

39 (2.4)

6 (1.0)

2 (0.9)

8 (1.0)

Pyoderma gangrenosum

5 (0.5)

8 (1.5)

13 (0.8)

3 (0.5)

N/A

3 (0.4)

Primary sclerosing cholangitis

22 (2.0)

2 (0.4)

24 (1.5)

32 (5.1)

5 (2.4)

37 (4.4)

Thrombotic complications

11 (1.0)

5 (0.9)

16 (1.0)

3 (0.5)

7 (3.3)

10 (1.2)

None reported

782 (72.6)

356 (67.6)

1138 (70.9)

477 (76.3)

157 (74.4)

634 (75.8)

Treatment received at baselinec, n (%)

Aminosalicylates

176 (16.3)

93 (17.6)

269 (16.8)

349 (55.8)

105 (49.8)

454 (54.3)

Antibioticsd

30 (2.8)

27 (5.1)

57 (3.6)

–

–

–

Biologics

      

Anti-TNFα

584 (54.2)

345 (65.5)

929 (57.9)

249 (39.8)

124 (58.8)

373 (44.6)

Anti-integrins

175 (16.2)

96 (18.2)

271 (16.9)

172 (27.5)

49 (23.2)

221 (26.4)

Ustekinumab

322 (29.9)

179 (34.0)

501 (31.2)

76 (12.2)

36 (17.1)

112 (13.4)

Corticosteroids

313 (29.1)

190 (36.1)

503 (31.4)

215 (34.4)

82 (38.9)

297 (35.5)

Immunomodulatorse

409 (38.0)

230 (43.6)

639 (39.8)

209 (33.4)

83 (39.3)

292 (34.9)

JAK inhibitor

10 (0.9)

9 (1.7)

19 (1.2)

50 (8.0)

29 (13.7)

79 (9.4)

Number of IBD surgeries

0

381 (35.4)

170 (32.3)

551 (34.4)

344 (55.0)

125 (59.2)

469 (56.1)

1

75 (7.0)

42 (8.0)

117 (7.3)

8 (1.3)

2 (0.9)

10 (1.2)

2+

78 (7.2)

25 (4.7)

103 (6.4)

10 (1.6)

1 (0.5)

11 (1.3)

Missing

543 (50.4)

290 (55.0)

833 (51.9)

263 (42.1)

83 (39.3)

346 (41.4)

  1. aIL-22 ≤ LLOQ.
  2. bIL-22 > LLOQ.
  3. cPatients may have received ≥ 1 type of treatment.
  4. dIncluding ciprofloxacin, clarithromycin, metronidazole, and rifaximin.
  5. eIncluding azathioprine, cyclosporine, mercaptopurine, methotrexate, and tacrolimus.
  6. CD Crohn’s disease, IBD inflammatory bowel disease, IL-22 interleukin-22, JAK Janus kinase, TNF tumor necrosis factor, sCDAI short Crohn’s disease activity index measuring disease severity, UC ulcerative colitis, UCDAI ulcerative colitis disease activity index measuring disease severity.
Back to article page